dr4 agonist Search Results


dr4 receptor agonist antibodies  (Human Genome Sciences (HGS)
90
Human Genome Sciences (HGS dr4 receptor agonist antibodies
Dr4 Receptor Agonist Antibodies, supplied by Human Genome Sciences (HGS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dr4+agonist/us10618949-188-20-28?v=Human+Genome+Sciences+%28HGS
Average 90 stars, based on 1 article reviews
dr4 receptor agonist antibodies - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
agonistic monoclonal dr4  (Takeda)
86
Takeda agonistic monoclonal dr4
Figure 1 Melanoma cell lines subdivide into positive and negative for <t>death</t> <t>receptor</t> <t>4</t> <t>(DR4).</t> (A) Surface expression of DR4 and death receptor 5 (DR5) was analyzed by fluorescence-activated cell sorting analysis in seven human melanoma cell lines and in cultures of normal human melanocytes (NHM). Median values obtained for melanoma cell lines (two independent experiments) and for NHM (three independent cul- tures) were normalized with respect to the negative control (primary antibody omitted). Dark bars are representative for DR4 and white bars for DR5, respectively. (B) Examples of DR4-positive cell lines (A-375, SK-Mel-13) and of DR4-negative cells (Mel-HO, SK-Mel-23) as well as of NHM are given. Cells were labeled with specific <t>monoclonal</t> (TRAIL)- R1/DR4 and TRAIL-R2/DR5 antibodies (filled graphs) as well as with an isotypic control IgG1 mouse monoclonal antibody (open graphs), re- spectively. A shift to the right side indicates death receptor surface expression. (C) Preparations of total protein of seven melanoma cell lines and of five cultures of NHM were analyzed by western blotting for DR4 and DR5 expression. Equal protein amounts (25 mg per lane) were separated by SDS-PAGE. Consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. Arrows indicate mo- lecular weights of identified protein bands. A highly comparable pattern of protein bands was obtained in a second experiment started from independently grown cell cultures. (D) SK-Mel-13 cells transiently transfected with two different concentrations of DR4 and DR5 expres- sion plasmids (SKM-13a: 0.1 mg per mL; SKM13b: 0.2 mg per mL) were investigated 48 h after transfection by western blot analysis for DR4 and DR5 (SDS-PAGE, 40 mg total protein per lane). Expression was compared with the basic expression in untransfected SK-Mel-13 and A-375 cells. Two independent series of transfection experiments have been performed, which revealed the same result.
Agonistic Monoclonal Dr4, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dr4+agonist/10__1111_slash_j__0022___202x__2005__23900__x-31-10-59?v=Takeda
Average 86 stars, based on 1 article reviews
agonistic monoclonal dr4 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Figure 1 Melanoma cell lines subdivide into positive and negative for death receptor 4 (DR4). (A) Surface expression of DR4 and death receptor 5 (DR5) was analyzed by fluorescence-activated cell sorting analysis in seven human melanoma cell lines and in cultures of normal human melanocytes (NHM). Median values obtained for melanoma cell lines (two independent experiments) and for NHM (three independent cul- tures) were normalized with respect to the negative control (primary antibody omitted). Dark bars are representative for DR4 and white bars for DR5, respectively. (B) Examples of DR4-positive cell lines (A-375, SK-Mel-13) and of DR4-negative cells (Mel-HO, SK-Mel-23) as well as of NHM are given. Cells were labeled with specific monoclonal (TRAIL)- R1/DR4 and TRAIL-R2/DR5 antibodies (filled graphs) as well as with an isotypic control IgG1 mouse monoclonal antibody (open graphs), re- spectively. A shift to the right side indicates death receptor surface expression. (C) Preparations of total protein of seven melanoma cell lines and of five cultures of NHM were analyzed by western blotting for DR4 and DR5 expression. Equal protein amounts (25 mg per lane) were separated by SDS-PAGE. Consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. Arrows indicate mo- lecular weights of identified protein bands. A highly comparable pattern of protein bands was obtained in a second experiment started from independently grown cell cultures. (D) SK-Mel-13 cells transiently transfected with two different concentrations of DR4 and DR5 expres- sion plasmids (SKM-13a: 0.1 mg per mL; SKM13b: 0.2 mg per mL) were investigated 48 h after transfection by western blot analysis for DR4 and DR5 (SDS-PAGE, 40 mg total protein per lane). Expression was compared with the basic expression in untransfected SK-Mel-13 and A-375 cells. Two independent series of transfection experiments have been performed, which revealed the same result.

Journal: Journal of Investigative Dermatology

Article Title: Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

doi: 10.1111/j.0022-202x.2005.23900.x

Figure Lengend Snippet: Figure 1 Melanoma cell lines subdivide into positive and negative for death receptor 4 (DR4). (A) Surface expression of DR4 and death receptor 5 (DR5) was analyzed by fluorescence-activated cell sorting analysis in seven human melanoma cell lines and in cultures of normal human melanocytes (NHM). Median values obtained for melanoma cell lines (two independent experiments) and for NHM (three independent cul- tures) were normalized with respect to the negative control (primary antibody omitted). Dark bars are representative for DR4 and white bars for DR5, respectively. (B) Examples of DR4-positive cell lines (A-375, SK-Mel-13) and of DR4-negative cells (Mel-HO, SK-Mel-23) as well as of NHM are given. Cells were labeled with specific monoclonal (TRAIL)- R1/DR4 and TRAIL-R2/DR5 antibodies (filled graphs) as well as with an isotypic control IgG1 mouse monoclonal antibody (open graphs), re- spectively. A shift to the right side indicates death receptor surface expression. (C) Preparations of total protein of seven melanoma cell lines and of five cultures of NHM were analyzed by western blotting for DR4 and DR5 expression. Equal protein amounts (25 mg per lane) were separated by SDS-PAGE. Consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. Arrows indicate mo- lecular weights of identified protein bands. A highly comparable pattern of protein bands was obtained in a second experiment started from independently grown cell cultures. (D) SK-Mel-13 cells transiently transfected with two different concentrations of DR4 and DR5 expres- sion plasmids (SKM-13a: 0.1 mg per mL; SKM13b: 0.2 mg per mL) were investigated 48 h after transfection by western blot analysis for DR4 and DR5 (SDS-PAGE, 40 mg total protein per lane). Expression was compared with the basic expression in untransfected SK-Mel-13 and A-375 cells. Two independent series of transfection experiments have been performed, which revealed the same result.

Article Snippet: For selective receptor targeting, recombinant TRAIL derivatives as well as agonistic monoclonal DR4 and Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5 Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1010 DR5 antibodies have been developed, and have also been tested to be efficient in mice (Takeda et al, 2004; Kelley et al, 2005).

Techniques: Expressing, FACS, Negative Control, Labeling, Control, Western Blot, SDS Page, Staining, Transfection

Figure 3 Strong caspase activation in death receptor 4 (DR4)-positive me- lanoma cells. Western blot experiments for capase-8, -10, -9, -3, -7, Bid, XIAP, and DFF45 are shown for seven investigated melanoma cell lines. Proteins were extracted from cultures 4 h after TRAIL treatment ( þ ) and from parallel controls (). For caspase-8 and XIAP, two dif- ferent exposure times were selected for visualization of the uncleaved and the cleaved forms, respectively. Equal amounts of proteins (25 mg per lane) were loaded, and consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. Molecular weights of proforms and cleavage products are indicated. Two experiments per- formed for each cell line starting from independent cultures revealed highly similar results.

Journal: Journal of Investigative Dermatology

Article Title: Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

doi: 10.1111/j.0022-202x.2005.23900.x

Figure Lengend Snippet: Figure 3 Strong caspase activation in death receptor 4 (DR4)-positive me- lanoma cells. Western blot experiments for capase-8, -10, -9, -3, -7, Bid, XIAP, and DFF45 are shown for seven investigated melanoma cell lines. Proteins were extracted from cultures 4 h after TRAIL treatment ( þ ) and from parallel controls (). For caspase-8 and XIAP, two dif- ferent exposure times were selected for visualization of the uncleaved and the cleaved forms, respectively. Equal amounts of proteins (25 mg per lane) were loaded, and consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. Molecular weights of proforms and cleavage products are indicated. Two experiments per- formed for each cell line starting from independent cultures revealed highly similar results.

Article Snippet: For selective receptor targeting, recombinant TRAIL derivatives as well as agonistic monoclonal DR4 and Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5 Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1010 DR5 antibodies have been developed, and have also been tested to be efficient in mice (Takeda et al, 2004; Kelley et al, 2005).

Techniques: Activation Assay, Western Blot, Staining, Expressing

Figure 5 Blocking death receptor 4 (DR4) prevents apoptosis in melanoma cells positive for both receptors. Subconfluent cultures of four me- lanoma cell lines were pre-incubated for 1 h with blocking antibodies for DR4 and DR5, respectively, before starting treatment with TRAIL (20 ng per mL, for another 6 h). Relative values for DNA fragmentation were calculated with respect to the basic apoptotic rates determined for untreated controls (set to 1, separately for each cell line). Mean values and SD of three independent experiments (A-375, SK-Mel-13) and of two experiments (Mel-HO, SK-Mel-19) are shown, each exper- iment itself consisted of triple values.

Journal: Journal of Investigative Dermatology

Article Title: Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

doi: 10.1111/j.0022-202x.2005.23900.x

Figure Lengend Snippet: Figure 5 Blocking death receptor 4 (DR4) prevents apoptosis in melanoma cells positive for both receptors. Subconfluent cultures of four me- lanoma cell lines were pre-incubated for 1 h with blocking antibodies for DR4 and DR5, respectively, before starting treatment with TRAIL (20 ng per mL, for another 6 h). Relative values for DNA fragmentation were calculated with respect to the basic apoptotic rates determined for untreated controls (set to 1, separately for each cell line). Mean values and SD of three independent experiments (A-375, SK-Mel-13) and of two experiments (Mel-HO, SK-Mel-19) are shown, each exper- iment itself consisted of triple values.

Article Snippet: For selective receptor targeting, recombinant TRAIL derivatives as well as agonistic monoclonal DR4 and Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5 Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1010 DR5 antibodies have been developed, and have also been tested to be efficient in mice (Takeda et al, 2004; Kelley et al, 2005).

Techniques: Blocking Assay, Incubation

Figure 6 Block of apoptotic cascades by death receptor 4 (DR4) antagonists in A-375 and SK-Mel-13. Western blot analysis for capase-8, -3 and -7 as well as for XIAP and DFF45 are shown for A-375 and SK-Mel-13. Cells were pre-incubated with blocking antibodies for 1 h before start- ing TRAIL treatment (20 ng per mL, for another 4 h). Equal amounts of proteins (25 mg per lane) were loaded, and consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. The experiment was performed twice starting from independent cul- tures, and revealed highly comparable results.

Journal: Journal of Investigative Dermatology

Article Title: Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

doi: 10.1111/j.0022-202x.2005.23900.x

Figure Lengend Snippet: Figure 6 Block of apoptotic cascades by death receptor 4 (DR4) antagonists in A-375 and SK-Mel-13. Western blot analysis for capase-8, -3 and -7 as well as for XIAP and DFF45 are shown for A-375 and SK-Mel-13. Cells were pre-incubated with blocking antibodies for 1 h before start- ing TRAIL treatment (20 ng per mL, for another 4 h). Equal amounts of proteins (25 mg per lane) were loaded, and consistent blotting was proven by Ponceau staining and by evaluation of b-actin expression. The experiment was performed twice starting from independent cul- tures, and revealed highly comparable results.

Article Snippet: For selective receptor targeting, recombinant TRAIL derivatives as well as agonistic monoclonal DR4 and Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5 Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1010 DR5 antibodies have been developed, and have also been tested to be efficient in mice (Takeda et al, 2004; Kelley et al, 2005).

Techniques: Blocking Assay, Western Blot, Incubation, Staining, Expressing

Figure 7 Significant expression of both TRAIL death receptors in melanoma biopsies. The expression level of death receptor 4 (DR4) and death receptor 5 (DR5) was examined by immunohistochemistry in primary tumors from 40 patients with nod- ular or superficial-spreading melanoma. Three examples are shown (left side) with strong expression of both receptors (pa- tient A), strong expression of DR4, and weak expression of DR5 (patient B), as well as with missing expression of DR4 and strong expression of DR5 (patient C). Immunocytochemistry for melanoma cell lines A-375, SK-Mel-13, and SK-Mel-23 shown on the right side proved the specificity of the antibodies applied and demonstrated a comparable situation in vitro and in vivo with respect to re- ceptor expression. Negative controls for immunohistochemistry and for immuno- cytochemistry (no primary antibody) as well as magnification scales are indicated below.

Journal: Journal of Investigative Dermatology

Article Title: Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

doi: 10.1111/j.0022-202x.2005.23900.x

Figure Lengend Snippet: Figure 7 Significant expression of both TRAIL death receptors in melanoma biopsies. The expression level of death receptor 4 (DR4) and death receptor 5 (DR5) was examined by immunohistochemistry in primary tumors from 40 patients with nod- ular or superficial-spreading melanoma. Three examples are shown (left side) with strong expression of both receptors (pa- tient A), strong expression of DR4, and weak expression of DR5 (patient B), as well as with missing expression of DR4 and strong expression of DR5 (patient C). Immunocytochemistry for melanoma cell lines A-375, SK-Mel-13, and SK-Mel-23 shown on the right side proved the specificity of the antibodies applied and demonstrated a comparable situation in vitro and in vivo with respect to re- ceptor expression. Negative controls for immunohistochemistry and for immuno- cytochemistry (no primary antibody) as well as magnification scales are indicated below.

Article Snippet: For selective receptor targeting, recombinant TRAIL derivatives as well as agonistic monoclonal DR4 and Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL-R1/DR4, TRAIL receptor 1/death receptor 4; TRAIL-R2/DR5, TRAIL receptor 2/death receptor 5 Copyright r 2005 by The Society for Investigative Dermatology, Inc. 1010 DR5 antibodies have been developed, and have also been tested to be efficient in mice (Takeda et al, 2004; Kelley et al, 2005).

Techniques: Expressing, Immunohistochemistry, Immunocytochemistry, In Vitro, In Vivo